Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Zutphen – page 51

842 clinical trials in Zutphen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Zutphen at a glance
842
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

842 trials in Zutphen

Open in trial search

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety of Glepaglutide for Adults with Short Bowel Syndrome

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

Burkitt's lymphoma

Not recruiting

Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Malignant melanoma

Not recruiting

Study on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Colitis ulcerative

Not recruiting

Study on Vedolizumab for Patients with Active Ulcerative Colitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Alimentiv Inc.

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Study on Long-Term Safety and Effects of Pegcetacoplan for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Long-Term Safety Study of Fenfluramine Hydrochloride for Seizures in Patients with Dravet or Lennox-Gastaut Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Zutphen

What the registry says about research in the country

01 Respiratory Diseases

Clinical research focusing on respiratory conditions including innovative treatments for asthma and viral infections. Studies encompass evaluation of new vaccine combinations and safety assessments of inhalation devices.

  • RSV and COVID-19 vaccine co-administration
  • Moderate to severe asthma treatments
  • Chronic Obstructive Pulmonary Disease management
  • Bronchiectasis therapy

Investigations include both preventive measures and therapeutic interventions for respiratory conditions.

02 Cardiovascular Studies

Comprehensive research into cardiovascular health, examining treatments for various heart conditions and prevention of major cardiac events.

  • Atherosclerotic Cardiovascular Disease
  • Heart Failure Management
  • Post-Heart Attack Treatment
  • Acute Coronary Syndrome

Focus on innovative therapies and interventions to improve patient outcomes in heart-related conditions.

03 Oncology Research

Advanced studies in lung cancer treatment and innovative therapeutic approaches for various cancer types.

  • Non-Small Cell Lung Cancer therapies
  • Immunotherapy optimization
  • Mantle Cell Lymphoma treatment

Evaluating novel treatment combinations and immunotherapy approaches for better patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.